Contineum Therapeutics, Inc. (CTNM) — Stock Score Summary

Contineum Therapeutics, Inc. (CTNM) has a MoatMap StockRank of 46/100 based on Quality (42/100), Value (39/100), and Momentum (51/100) factor scores. The current signal is HOLD. Contineum Therapeutics is a clinical-stage biotechnology company. It has no commercialized products, no revenues, and is highly speculative, failing both the Terry Smith quality lens and the Warren Buffett margin of safety requirement.

Contineum Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing novel small molecule therapies for neurological, inflammatory, and fibrotic diseases. The company's competitive potential hinges on the successful progression of its pipeline, including its lead candidate NIM8 for multiple sclerosis, through rigorous clinical trials to address significant unmet medical needs.

Key Financial Metrics

Price$11.43
Market Cap$498M
P/E (Forward)-6.80
Price/Book1.85
Return on Equity-26.9%
Return on Invested Capital-25.5%
Debt/Equity2.78
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-39M

Contineum Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Contineum Therapeutics, Inc.’s (CTNM) StockRank?
MoatMap’s StockRank for Contineum Therapeutics, Inc. (CTNM) is 46/100, with a Hold signal. It is a composite of Quality (42), Value (39), and Momentum (51) factor ranks across MoatMap’s 19,000+ stock universe.
Does Contineum Therapeutics, Inc. have an economic moat?
Contineum Therapeutics, Inc. (CTNM) has a Quality factor score of 42/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Contineum Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Contineum Therapeutics, Inc. (CTNM) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Contineum Therapeutics, Inc. in?
Contineum Therapeutics, Inc. (CTNM) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksCTNM deep dive reportAI ChampionsHow we score stocksSense-check another stock